Mediwheel <wellness@mediwheel.in>

Mon 3/18/2024 5:47 PM

To:PHC [MH-Ghaziabad] < phc.ghaziabad@manipalhospitals.com> Cc:customercare@mediwheel.in <customercare@mediwheel.in>



011-41195959

Hi Manipal Hospital,

The following booking has been confirmed. It is requested to honor the said booking & provide priority services to our client

Hospital

Package Name

: Mediwheel Full Body Health Checkup Male Above 40

Name

Patient Package : MediWheel Full Body Health Checkup Male 50 To 60

Contact Details : 9582846362

Appointment

Date

: 19-03-2024

Confirmation

Status

: Booking Confirmed

Preferred Time : 8:30am

Member Inform	ation	
Booked Member Name		Gender
OMVEER SINGH	54 year	Male

We request you to facilitate the employee on priority.

Thanks, Mediwheel Team Please Download Mediwheel App





You have received this mail because your e-mail ID is registered with Arcofemi Healthcare Limited This is a system-generated e-mail please don't reply to this message.

Please visit to our Terms & Conditions for more information. Click here to unsubscribe.

ag 2004 - 25, Anodem Hyshboare Published (Modisched)

To,

Health checkup at tie-up Ctr

HealthChkup Authorisatn letter



Union Bank of India

RO - GHAZIABAD GHAZIABAD,, GHAZIABAD,, Uttar Pradesh, - 0

The Chief Medical Officer

M/S Mediwheel https://mediwheel.in/signup011-41195959(A brand name of Arcofemi Healthcare Ltd), Mumbai400021 Dear Sir,

Tie-up arrangement for Health Checkup under Health Checkup

50-60 Male

Shri/Smt./Kum. SINGH, OMVEER

P.F. No. 607896

Designation:

ASSISTANT MANAGER(RCoC)

Checkup for Financial Year

Approved Charges Rs. 2023-

2024
. The above mentioned staff member of our Branch/Office desires to undergo Health Checkup at your Hospital/Centre/Clinic, under the tie-up arrangement entered into with you, by our bank.

Please send the receipt of the above payment and the relevant reports to our above address.

Thanking you

Yours Faithfully

(Signature of the Employee)

BRANCH MANAGERISENIOR MANAGER

PS. : Status of the application-

Ghaziabad





ओमवीर सिंह Omveer Singh जन्म तिथि/DOB: 15/03/1970 पुरुष/ MALE

7134 4091 2099 VID: 9153 7152 3885 3293



MERA AADHAAR, MERI PEHCHAN





भारतीय विशिष्ट पहचान प्राधिकरण

हु पता: C/O गजराज सिंह, एच न बी-114, महादेव गली, नई कर्हेरा के कॉलोनी, मोहन नगर, गाजियाबाद, हुं उत्तर प्रदेश - 201007

े उत्तर प्रदेश - 20 Address :

C/O Gajraj Singh, h no b-114, mahadev gali, new karhera colony, Mohan Nagar, Ghaziabad, Uttar Pradesh - 201007






 \bowtie

www

- BORDERLINE ECG -









INVESTIGATION REPORT

Patient Name

MR OMVEER SINGH

Location

Ghaziabad

Age/Sex

54Year(s)/male

Visit No

: V0000000001-GHZB

MRN No

MH011785026

Order Date

:19/03/2024

Ref. Doctor

Dr. ABHISHEK SINGH

Report Date

:19/03/2024

Echocardiography

Final Interpretation

- 1. No RWMA, LVEF=60%.
- 2. Mild concentric LVH.
- 3. Grade I LV diastolic dysfunction.
- 4. No MR, No AR.
- 5. Trace TR, Normal PASP.
- 6. No intracardiac clot/mass/pericardial pathology.
- 7. IVC normal

Chambers & valves:

- **Left Ventricle:** It is normal sized.
- <u>Left Atrium:</u> It is normal sized.
- Right Atrium: It is normal sized.
- Right Ventricle: It is normal sized.
- Aortic Valve: It appears normal.
- Mitral Valve: Opens normally. Subvalvular apparatus appear normal.
- <u>Tricuspid Valve:</u> Trace TR, Normal PASP.
- Pulmonic Valve: It appears normal.
- Main Pulmonary artery & its branches: Appear normal.
- **Pericardium:** There is no pericardial effusion.

Description:

LV is normal size with normal contractility.

Manipal Hospital, Ghaziabad

NH - 24, Hapur Road, Ghaziabad, Uttar Pradesh - 201 002

P: 0120-3535353

Manipal Health Enterprises Private Limited

CIN: U85110KA2003PTC033055

Regd. Off. The Annexe, #98/2, Rustom Bagh, Off. HAL Airport Road, Bengaluru - 560 017 P +91 80 4936 0300 E info@manihospitals.com www.manipalhospitals.com





Name

MR OMVEER SINGH

Age

54 Yr(s) Sex: Male

Registration No

MH011785026

Lab No

202403002782

Patient Episode

H18000001942

Collection Date:

19 Mar 2024 08:55

Referred By

HEALTH CHECK MGD

Reporting Date: 19 Mar 2024 16:23

Receiving Date

19 Mar 2024 08:55

BIOCHEMISTRY

TEST

RESULT

UNIT

ng/ml

ug/ dl

µIU/mL

BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

[0.610-1.630]

[4.680-9.360]

[0.250 - 5.000]

THYROID PROFILE, Serum

T3 - Triiodothyronine (ELFA)	1.240
T4 - Thyroxine (ELFA)	7.520
Thyroid Stimulating Hormone	2.700

NOTE:

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page 1 of 3





Name

MR OMVEER SINGH

Age

54 Yr(s) Sex :Male

Registration No

MH011785026

Lab No

202403002782

Patient Episode

H18000001942

Collection Date:

19 Mar 2024 08:55

Referred By

HEALTH CHECK MGD

Reporting Date: 19 Mar 2024 12:13

Receiving Date

19 Mar 2024 08:55

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

PROSTATE SPECIFIC ANTIGEN (PSA-Total):

0.430

BIOCHEMISTRY

ng/mL

[<3.500]

Method : ELFA

Note :1. This is a recommended test for detection of prostate cancer along with Digital Recta Examination (DRE) in males above 50 years of age

damage caused by BPH, prostatitis, or prostate cancer may increase circulating PSA levels. 2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy

3. PSA levels may appear consistently elevated / depressed due to the interference by hetero antibodies & nonspecific protein binding

4. Immediate PSA testing following digital rectal examination, ejaculation, prostatic massag indwelling catheterization, and ultrasonography and needle biopsy of prostate is not recomme as they falsely elevate levels

5. PSA values regardless of levels should not be interpreted as absolute evidence of the pre or absence of disease. All values should be correlated with clinical findings and results of other investigations

6. Sites of Non - prostatic PSA production are breast epithelium, salivary glands, peri urethral

& anal glands, cells of male urethra && breast mil

7. Physiological decrease in PSA level by 18% has been observed in hospitalized / sedentary patients either due to supine position or suspended sexual activity

Recommended Testing Intervals

- * Pre-operatively (Baseline)
- * 2-4 days post-operatively
- * Prior to discharge from hospital
- * Monthly follow-up if levels are high or show a rising trend

Page 2 of 3





Ghaziabad - 201002 Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Name

MR OMVEER SINGH

Age

54 Yr(s) Sex: Male

Registration No

MH011785026

Lab No

202403002782

Patient Episode

H18000001942

Collection Date:

19 Mar 2024 08:55

Referred By

HEALTH CHECK MGD

Reporting Date: 19 Mar 2024 18:33

Receiving Date

19 Mar 2024 08:55

This report is subject to the to-

BLOOD BANK

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

Blood Group & Rh typing

O Rh(D) Positive

Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

Page 3 of 3

NOTE:

- Abnormal Values

-----END OF REPORT-----

Dr. Alka Dixit Vats **Consultant Pathologist**







Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Name

: MR OMVEER SINGH

Age

54 Yr(s) Sex :Male

Registration No

: MH011785026

Lab No

202403002782

Patient Episode

: H18000001942

Collection Date:

19 Mar 2024 08:55

Referred By

: HEALTH CHECK MGD

This report is subject to the tor

Reporting Date:

19 Mar 2024 11:23

Receiving Date

: 19 Mar 2024 08:55

HAEMATOLOGY

	TEST	RESULT	UNIT BIO	LOGICAL REFERENCE INTERVAL
	COMPLETE BLOOD COUNT (AUTOMAT	ED)	SPECIMEN-EDTA	Whole Blood
	RBC COUNT (IMPEDENCE)	4.72	millions/cumm	[4.50-5.50]
)	HEMOGLOBIN	14.1	g/dl	[13.0-17.0]
	Method:cyanide free SLS-color	imetry		
	HEMATOCRIT (CALCULATED)	43.3	00	[40.0-50.0]
	MCV (DERIVED)	91.7	fL	[83.0-101.0]
	MCH (CALCULATED)	29.9	bà	[25.0-32.0]
	MCHC (CALCULATED)	32.6	g/dl	[31.5-34.5]
	RDW CV% (DERIVED)	12.1	%	[11.6-14.0]
	Platelet count	234	x 10³ cells/cu	mm [150-410]
	Method: Electrical Impedance			
	MPV (DERIVED)	12	fL	
	WBC COUNT (TC) (IMPEDENCE) DIFFERENTIAL COUNT (VCS TECHNOLOGY/MICROSCOPY)	8.37	x 10³ cells/cu	mm [4.00-10.00]
	Neutrophils	54.0	્ર	140 0 00 01
	Lymphocytes	36.0	8	[40.0-80.0]
	Monocytes	5.0	9	[20.0-40.0]
	Eosinophils	5.0	90	[2.0-10.0]
	Basophils	0.0	90 .	[1.0-6.0]
	Dagobutto	0.0	•	[0.0-2.0]
	ESR	20.0 #	mm/1sthour	-0.0]

Page 1 of 9







Name

: MR OMVEER SINGH

Age

54 Yr(s) Sex :Male

Registration No

: MH011785026

Lab No

202403002782

Patient Episode

: H18000001942

Collection Date:

19 Mar 2024 09:32

Referred By

: HEALTH CHECK MGD

Reporting Date:

19 Mar 2024 16:47

Receiving Date

: 19 Mar 2024 09:32

CLINICAL PATHOLOGY

ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

MACROSCOPIC DESCRIPTION

Colour

PALE YELLOW

(Pale Yellow - Yellow)

Appearance Reaction[pH]

CLEAR

5.0

(4.6 - 8.0)

Specific Gravity

1.015

(1.003 - 1.035)

CHEMICAL EXAMINATION

Protein/Albumin

Negative

(NEGATIVE)

Glucose

NIL

(NIL)

Ketone Bodies

Negative

(NEGATIVE)

Urobilinogen

Normal

(NORMAL)

MICROSCOPIC EXAMINATION (Automated/Manual)

Pus Cells

1-2 /hpf

(0-5/hpf)(0-2/hpf)

RBC

NIL

Epithelial Cells

1 - 2

/hpf

CASTS

NIL

Crystals

NIL NIL

Bacteria OTHERS

NIL

Page 2 of 9







Age

Ghaziabad - 201002 Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Name

: MR OMVEER SINGH

54 Yr(s) Sex :Male

Registration No

: MH011785026

Lab No : 2

Collection Date:

Patient Episode

: H18000001942

202403002782

Referred By

: HEALTH CHECK MGD

19 Mar 2024 10:03

Receiving Date

: 19 Mar 2024 10:03

Reporting Date: 19 Mar 2024 18:00

CLINICAL PATHOLOGY

STOOL COMPLETE ANALYSIS

Specimen-Stool

Macroscopic Description

Colour

Consistency

Blood Mucus

Occult Blood

BROWN

Semi Solid

Absent

Absent

NEGATIVE

Microscopic Description

Ova

Cyst

Fat Globules

Pus Cells

RBC

Absent

Absent

Absent

NIL

NIL

Page 3 of 9







Ghaziabad - 201002 Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Name

: MR OMVEER SINGH

Registration No

: MH011785026

Patient Episode

: H18000001942

Referred By

: HEALTH CHECK MGD

Receiving Date

: 19 Mar 2024 08:55

Age

54 Yr(s) Sex :Male

Lab No

202403002782

Collection Date:

19 Mar 2024 08:55

Reporting Date:

19 Mar 2024 18:18

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Glycosylated Hemoglobin

Specimen: EDTA

Method: HPLC

HbA1c (Glycosylated Hemoglobin)

6.3 #

9

[0.0-5.6]

As per American Diabetes Association (ADA

HbA1c in %

Non diabetic adults >= 18 years <5.7 Prediabetes (At Risk)5.7-6.4

Diagnosing Diabetes >= 6.5

Estimated Average Glucose (eAG)

134

mg/dl

Comments: HbAlc provides an index of average blood glucose levels over the past 8-12 weeks and is a much better indicator of long term glycemic control.

Serum LIPID PROFILE

Serum TOTAL CHOLESTEROL	194	mg/dl	[<200]	
Method:Oxidase, esterase, peroxide			Moderate risk:200-239	
EDICINGED TO COLUMN COL		10	High risk:>240	
TRIGLYCERIDES (GPO/POD)	164 #	mg/dl	[<150]	
			Borderline high:151-199	
			High: 200 - 499	
UDI GUOI EGERDO.			Very high:>500	
HDL- CHOLESTEROL	56	mg/dl	[35-65]	
Method: Enzymatic Immunoimhibition				
VLDL- CHOLESTEROL (Calculated)	33	mg/dl	[0-35]	
CHOLESTEROL, LDL, CALCULATED	105.0	mg/dl	[<120.0]	
			Near/	
Above optimal-100-129			* •	

Borderline High: 130-159 High Risk: 160-189

Page 4 of 9







Ghaziabad - 201002 Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Landcian Gommis,

LABORATORY REPORT

Name

: MR OMVEER SINGH

Registration No

: MH011785026

Patient Episode

: H18000001942

Referred By

: HEALTH CHECK MGD

Receiving Date

: 19 Mar 2024 08:55

Age

54 Yr(s) Sex: Male

Lab No

202403002782

Collection Date:

19 Mar 2024 08:55

Reporting Date:

19 Mar 2024 12:13

BIOCHEMISTRY

	TEST T.Chol/HDL.Chol	RE ratio(Calculated)	SULT	3.5	UNIT	<pre>8 BIOLOGICAL REFERENCE INTERVAL</pre>	te
)	DL.CHOL/HDL.CHOI	Ratio(Calculated)		1.9	2	<pre><3 Optimal 3-4 Borderline >6 High Risk</pre>	

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

KIDNEY PROFILE

	Specimen: Serum			
	UREA	19.7	mg/dl	[15.0-40.0]
	Method: GLDH, Kinatic assay		-22%	[,0 10.0]
	BUN, BLOOD UREA NITROGEN	9.2	mg/dl	[8.0-20.0]
1	Method: Calculated			1 8 8 8 8 8
	CREATININE, SERUM	0.75	mg/dl	[0.70-1.20]
	Method: Jaffe rate-IDMS Standardization URIC ACID			
	Method:uricase PAP	5.2	mg/dl	[4.0-8.5]
	THE HOU. WII CASE FAF			
	SODIUM, SERUM	136.40	mmol/L	1106 00
	*	130.40	ишот/ п	[136.00-144.00]
	POTASSIUM, SERUM	4.05	mmol/L	[3.60-5.10]
	SERUM CHLORIDE	102.7	mmol/L	[101.0-111.0]
	Method: ISE Indirect	THE PROPERTY OF ST.		[101.0-111.0]

Page 5 of 9







Name

: MR OMVEER SINGH

Registration No

: MH011785026

Patient Episode

: H18000001942

Referred By

: HEALTH CHECK MGD

Receiving Date

: 19 Mar 2024 08:55

Age

54 Yr(s) Sex :Male

Lab No

202403002782

Collection Date:

19 Mar 2024 08:55

Reporting Date:

19 Mar 2024 12:13

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

eGFR (calculated)

Technical Note

104.0

ml/min/1.73sq.m

[>60.0]

eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis Icterus / Lipemia.

LIVER FUNCTION TEST

BILIRUBIN - TOTAL Method: D P D	0.56	mg/dl	[0.30-1.20]
BILIRUBIN - DIRECT Method: DPD	0.10	mg/dl	[0.00-0.30]
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.46	mg/dl	[0.10-0.90]
TOTAL PROTEINS (SERUM) Method: BIURET	7.50	gm/dl	[6.60-8.70]
ALBUMIN (SERUM) Method: BCG	4.45	g/dl	[3,50-5,20]
GLOBULINS (SERUM) Method: Calculation	3.10	gm/dl	[1.80-3.40]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.46		[1.00-2.50]
AST(SGOT) (SERUM) Method: IFCC W/O P5P	34.00	U/L	[0.00-40.00]

Page 6 of 9





Name : MR OMVEER SINGH Age : 54 Yr(s) Sex :Male

 Patient Episode
 : H18000001942
 Collection Date : 19 Mar 2024 08:55

Referred By : HEALTH CHECK MGD Reporting Date : 19 Mar 2024 12:13

Receiving Date : 19 Mar 2024 08:55

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOL	OGICAL REFERENCE INTE	RVAL
ALT(SGPT) (SERUM) Method: IFCC W/O P5P	48.00		U/L	[17.00-63.00]	
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	70.0		IU/L	[32.0-91.0]	
GGT	31.0		U/L	[7.0-50.0]	

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

Page 7 of 9

----END OF REPORT---





Name

: MR OMVEER SINGH

Age

54 Yr(s) Sex :Male

Registration No

: MH011785026

Lab No

202403002783

Patient Episode

: H18000001942

Collection Date:

19 Mar 2024 08:55

Referred By

: HEALTH CHECK MGD

Reporting Date:

19 Mar 2024 12:14

Receiving Date

: 19 Mar 2024 08:55

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

GLUCOSE-Fasting

Specimen: Plasma

GLUCOSE, FASTING (F)

134.0 #

mg/dl

[70.0-110.0]

Method: Hexokinase

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases(e.g.galactosemia), Drugs-

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

Page 8 of 9

----END OF REPORT--





Name

: MR OMVEER SINGH

Age

54 Yr(s) Sex :Male

Registration No

: MH011785026

Lab No

202403002784

Patient Episode

: H18000001942

Collection Date:

19 Mar 2024 11:51

Referred By

: HEALTH CHECK MGD

Reporting Date:

19 Mar 2024 15:04

Receiving Date

: 19 Mar 2024 11:51

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

PLASMA GLUCOSE

Specimen:Plasma

GLUCOSE, POST PRANDIAL (PP), 2 HOURS

193.0 #

mg/dl

[80.0-140.0]

Method: Hexokinase

Note:

Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric emptying, brisk glucose absorption , post exercise

Page 9 of 9

-----END OF REPORT---





Name

: MR OMVEER SINGH

Age

54 Yr(s) Sex :Male

Registration No

: MH011785026

Lab No

202403002782

Patient Episode

: H18000001942

Collection Date:

19 Mar 2024 08:55

Referred By

: HEALTH CHECK MGD

Reporting Date:

19 Mar 2024 12:13

BIOLOGICAL REFERENCE INTERVAL

Receiving Date

TEST

: 19 Mar 2024 08:55

BIOCHEMISTRY

UNIT

RESULT

Serum LIPID PROFILE			
Serum TOTAL CHOLESTEROL	194	mg/dl	[<200]
Method:Oxidase, esterase, peroxide			Moderate risk:200-239
	4.64 11		High risk:>240
TRIGLYCERIDES (GPO/POD)	164 #	mg/dl	[<150]
			Borderline high: 151-199
			High: 200 - 499
HDT - CHOI FOREDOX	5.6	/ 17	Very high:>500
HDL- CHOLESTEROL	56	mg/dl	[35-65]
Method: Enzymatic Immunoimhibition			
VLDL- CHOLESTEROL (Calculated)	33	mg/dl	[0-35]
CHOLESTEROL, LDL, CALCULATED	105.0	mg/dl	[<120.0] Near/
Above optimal-100-129			Near/
Above optimal 100-129			Pordorline High 120 150
			Borderline High:130-159 High Risk:160-189
T.Chol/HDL.Chol ratio(Calculated)	3.5		<4.0 Optimal
remor/ HDB. ener lacto (carculated)	3.3		4.0-5.0 Borderline
			>6 High Risk
LDL.CHOL/HDL.CHOL Ratio(Calculated)	1.9		<3 Optimal
			3-4 Borderline
			>6 High Risk

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

Page1 of 1

-----END OF REPORT--





NAME	MR Omveer SINGH	STUDY DATE	19/03/2024 9:09AM
AGE / SEX	54 y / M	HOSPITAL NO.	MH011785026
ACCESSION NO.	R7081046	MODALITY	CR
REPORTED ON	19/03/2024 9:17AM	REFERRED BY	HEALTH CHECK MGD

XR- CHEST PA VIEW

FINDINGS:

LUNGS: Normal. TRACHEA: Normal. CARINA: Normal.

RIGHT AND LEFT MAIN BRONCHI: Normal.

PLEURA: Normal. HEART: Normal.

RIGHT HEART BORDER: Normal. LEFT HEART BORDER: Normal. PULMONARY BAY: Normal. PULMONARY HILA: Normal.

AORTA: Normal.

THORACIC SPINE: Normal.

OTHER VISUALIZED BONES: Normal. VISUALIZED SOFT TISSUES: Normal.

DIAPHRAGM: Normal.

VISUALIZED ABDOMEN: Normal. VISUALIZED NECK: Normal.

IMPRESSION:

-No significant abnormality seen.

Please correlate clinically

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS

CONSULTANT RADIOLOGIST

*****End Of Report*****





NAME	MR Omveer SINGH	STUDY DATE	19/03/2024 9:06AM
AGE / SEX	54 y / M	HOSPITAL NO.	MH011785026
ACCESSION NO.	R7081047	MODALITY	US
REPORTED ON	19/03/2024 11:29AM	REFERRED BY	HEALTH CHECK MGD

USG ABDOMEN & PELVIS

FINDINGS

LIVER: appears normal in size (measures 144 mm) and shape but shows diffuse increase in liver echotexture,

in keeping with diffuse grade II fatty infiltration. Rest normal.

SPLEEN: Spleen is normal in size (measures 89 mm), shape and echotexture. Rest normal.

PORTAL VEIN: Appears normal in size and measures 10 mm.

COMMON BILE DUCT: Appears normal in size and measures 4 mm.

IVC, HEPATIC VEINS: Normal. BILIARY SYSTEM: Normal.

GALL BLADDER: Gall bladder is well distended. Wall thickness is normal and lumen is echofree. Rest normal.

PANCREAS: Pancreas is normal in size, shape and echotexture. Rest normal.

KIDNEYS: Bilateral kidneys are normal in size, shape and echotexture. Cortico-medullary differentiation is

maintained. Rest normal.

Right Kidney: measures 93 x 37 mm. Left Kidney: measures 97 x 47 mm. PELVI-CALYCEAL SYSTEMS: Compact.

NODES: Not enlarged. FLUID: Nil significant.

URINARY BLADDER: Urinary bladder is well distended. Wall thickness is normal and lumen is echofree. Rest

normal.

PROSTATE: Prostate is enlarged in size (measures $51 \times 36 \times 32$ mm with volume 31 cc) but normal in shape

and echotexture. Rest normal. SEMINAL VESICLES: Normal.

BOWEL: Visualized bowel loops appear normal.

IMPRESSION

- -Diffuse grade II fatty infiltration in liver.
- -Prostatomegaly.

Recommend clinical correlation.

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS

CONSULTANT RADIOLOGIST

******End Of Report*****